How Do Tremfya and Taltz Perform in Psoriatic Arthritis Trials?
Tremfya (guselkumab, Janssen) and Taltz (ixekizumab, Eli Lilly) both treat psoriatic arthritis (PsA) effectively, targeting IL-23 and IL-17 pathways respectively. Direct head-to-head trials are absent, so comparisons rely on separate phase 3 studies using ACR20/50/70 response rates (percentage of patients with 20%/50%/70% improvement in American College of Rheumatology criteria).
In the DISCOVER-2 trial (moderate-to-severe PsA, TNF-naive), Tremfya 100mg every 8 weeks hit ACR20 in 64% at week 24 (vs 50% placebo), ACR50 in 43%, ACR70 in 25%.[1] Taltz in SPIRIT-P1 (similar population, biologic-naive) achieved ACR20 in 71% at week 24 (vs 36% placebo), ACR50 in 51%, ACR70 in 29%; in SPIRIT-P2 (TNF-inadequate responders), ACR20 was 60% (vs 31% placebo).[2][3] Taltz edges out on ACR20/50 in biologic-naive patients, while Tremfya performs comparably or better in ACR70 for TNF-failures, but cross-trial differences in baselines limit firm conclusions.
Minimal disease activity (MDA, stringent composite including skin, joints, enthesitis) shows Taltz at 31-40% at week 24 vs Tremfya's 27-32%.[1][2]
Which Drug Sustains Responses Longer?
Both maintain efficacy through 52 weeks. Tremfya in DISCOVER-2: ACR20 72%, ACR50 55%, ACR70 37%.[1] Taltz in SPIRIT trials: ACR20 70-78%, ACR50 52-62%, ACR70 40-47%.[3] Taltz shows slightly higher ACR70 rates long-term, potentially due to deeper skin clearance (PASI90: 72% vs Tremfya's 64% at week 24).[2][1]
Radiographic progression (modified total Sharp score) is low for both: Tremfya inhibited in 69% (DISCOVER-2), Taltz in 84-96% (SPIRIT).[1][3]
Skin and Nail PsA Symptoms: Key Differentiator?
PsA often involves psoriasis. Taltz excels in skin: week 24 PASI90 (90% clearance) 72-82% vs Tremfya's 58-64%; PASI100 47% vs 38%.[1][2] For nails (NAPSI score), Taltz clears 60-70% at week 24 vs Tremfya's 40-50%.[3]
Enthesitis, Dactylitis, and Axial Involvement
Taltz resolves enthesitis (LEI=0) in 52-62% at week 24 vs Tremfya's 52-56%; dactylitis similar (70-80% resolution).[1][2] For axial PsA, Taltz (MAXIMISE trial) hit ASAS40 in 69% at week 16; Tremfya (DISCOVER) in 56%.[4][1] No clear winner.
Safety and Discontinuation Rates
Adverse events are comparable: serious infections 1-3%, no tuberculosis signals. Taltz has slightly higher injection-site reactions (15-20% vs 10-15%) and candidiasis (2-5% vs <1%). Discontinuation due to AEs: 2-5% for both at week 24.[1][2][3] Long-term safety favors neither decisively.
Real-World Data and Patient Factors
Observational studies (e.g., CorEvitas registry) show similar 1-year retention: ~70% for both, with Taltz preferred for severe skin/nails, Tremfya for gut comorbidities (Crohn's risk).[5] Choose based on phenotype: Taltz for skin-dominant PsA, Tremfya for joints/gut. Guidelines (EULAR/ACR) rank both highly, post-TNF.[6]
No evidence Tremfya works "better" overall—Taltz may lead in skin, Tremfya in joint/gut profiles—but individual response varies.
[1]: New England Journal of Medicine - DISCOVER-2
[2]: Lancet - SPIRIT-P1
[3]: Annals of Rheumatic Diseases - SPIRIT-P2
[4]: RMD Open - MAXIMISE
[5]: Rheumatology - CorEvitas PsA Registry
[6]: EULAR 2023 PsA Recommendations